You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雙鷺藥業(002038.SZ):含大麻葉提取物CBD通過“國產非特殊用途化粧品備案”
格隆匯 09-08 16:50

格隆匯9月8日丨雙鷺藥業(002038.SZ)公佈,公司於近日收到公司控股子公司海布生物科技(雲南)有限公司(“海布生物”)函,稱海布生物向雲南省藥品監督管理局申請的含大麻葉提取物CBD的“國產非特殊用途化粧品備案(首次備案)”近日已獲得審批通過(批准文號:雲G粧字2020001377)。

海布生物成立於2019年7月,註冊資本為5000萬元,由公司與國海聯合集團有限公司共同設立,公司持有海布生物70%股權。海布生物註冊地址為雲南省臨滄市雲縣愛華鎮新材料光伏產業園區,海布生物經營範圍為:植物種植及提取加工(含工業大麻、黃芪、白背三七、龍膽草等種植及成分提取、加工);種子繁育;工業大麻為原料的產品檢驗服務;食品、飲品、保健品、化粧品、藥品銷售;天然植物營養素的研發及提取;生物科技產品研發、生產、經營;貨物或技術進出口。目前海布生物已獲得工業大麻種植和生產許可,今年已完成3000畝的試種,計劃於10月底前收穫及進行CBD生產提取,其綜合利用計劃也將隨後展開。海布生物計劃明年將擴大種植面積和加工規模。

該產品上市後需要進一步加強市場推廣,同時公司針對食品、飲品、保健品、藥品的開發目前正在進行中。敬請廣大投資者謹慎決策,注意防範投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account